Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELARA long-term open-label extension of OV101 in Angelman syndrome
NL-OMON49727Phase 3Completed
- Sponsor
- Ovid Therapeutics
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gaboxadol in Angelman syndrome (AS), sponsored by Ovid Therapeutics. Primary endpoint: Incidence and severity of adverse events and serious adverse events. Started Oct 2020; status: completed.
02
Drugs
gaboxadol
03
Conditions
Angelman syndrome (AS)
Beyond the preview
Go deeper on NL-OMON49727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49727.